International Research Journal of Pharmacy and Medical Sciences
ISSN (Online): 2581-3277

The Role of Pharmaceutical Chemistry in the Design and Development of Targeted Medicines: Chemical Principles and Therapeutic Applications

Ayad Jirjees Dhulkefl*[1], Engie Aydin Kamal ALABBAS[1], Suad Shallal Shahatha[2]
[1]Department of Occupational Safety and Occupational Medicine Techniques, Northern Technical University, Kirkuk, Iraq.
[2]Department of Desert Development, Center of Desert Studies, University of Anbar, Anbar, Iraq
*Corresponding Author Email: eyad.cercis@ntu.edu.iq

Abstract—*The context of pharmaceutical research has reached the stage where drug discovery can be seen as the testing and development of medicants targeted at specific molecular components within disease processes, rather than merely identifying chemicals with a broad therapeutic potential. Pharmaceutical science has matured to a basic discipline of this age, providing tools of investigation of the relationships between structure and activity, and structure and selectivity. This review addresses how progress in pharmaceutical chemistry has contributed to targeted drug discovery, highlighting chemical methodologies for target identification, binding selectivity, and physicochemical properties optimization along with those for achieving target engagement and pharmacodynamic profile. In addition to outlining the principle therapeutic applications, effective in a variety of human diseases, the review also covers current mechanisms and trends in pharmaceutical chemistry.*

Keywords— *Drug Design; Molecular Drug Interactions; Pharmaceutical Chemistry; Pharmacological Selectivity; Targeted Drugs.*

I. INTRODUCTION

The development of a drug is an intricate multi-stage procedure which starts with the discovery of a biological target connected to the disease's pathogenic mechanism and ends in producing a completely safe, therapeutically effective therapeutic agent for human use [1]. Data obtained with conventional drug-discovery efforts have indicated that a large number of pharmacologically active molecules are lost at the latter stage of drug development because they lack adequate target-selectivity or show ubiquitous side effects due to interacting with untargeted biological systems [2]. Such limitations have prompted the necessity to develop tailored and rational approaches to improve therapeutic effectiveness, and reduce unwanted off-target side-effects [3]. Under this landscape, targeted medicines have become one of the major subjects in pharmaceutical and medical sciences since drug design is focused on developing drugs that can interact selectively with certain biological agents such as enzymes, receptors or regulatory proteins related to well-known cellular mechanisms. This shift has led to remarkable achievements of efficiency and safety in the new drug properties [4].

Indeed, pharmaceutical chemistry has made a major contribution in taking the key idea of targeted medicine and turning it into an operational drug discovery mindset by utilizing basic chemical principles to determine both the molecular architectures of biological targets and the interactions that underpin selective drug recognition [5]. As shown in Fig.1, pharmaceutical chemistry represents an efficient approach for the targeted design and development of drugs including identification of biological target, molecular designing and structural optimization through SAR (structure–activity relationship) studies [6]. This 'systems' view highlights the intimate relationship between chemical structure and biological activity that rational drug design depends on, and is likely to lead to safer and more potent patient targeted therapies [7].



Fig. 1. Diagram illustrating the role of pharmaceutical chemistry in targeted drug design and development.

II. THE CONCEPT OF TARGETED MEDICINES AND THEIR THERAPEUTIC IMPORTANCE

It is highlighted that targeted medicines belong to a novel generation of drug therapies in which knowledge of molecular

Ayad Jirjees Dhulkefl, Engie Aydin Kamal ALABBAS, and Suad Shallal Shahatha, "The Role of Pharmaceutical Chemistry in the Design and Development of Targeted Medicines: Chemical Principles and Therapeutic Applications," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 9, Issue 2, pp. 54-57, 2026.

basis of disease plays a critical role [8]. This strategy optimizes around a biological target that is central to the disease process and creates compounds that selectively alter activity at this target [9]. The therapeutic significance of this type of drug is the avoidance of side effects from interference with other biological systems which, in turn, would enhance treatment effectiveness and patient compliance [10]. The delivery of so-called "personalized" drugs will also permit a more personalized treatment based on the patient's biological characteristics and biology of their disease, which is one of precision medicine's greatest advances [11].

III. Chemical Principles in Targeted Drug Design

A. *Target Selection from a Chemical Perspective*

Target selection is the first step for drug target design. The choice is weighty, as it needs a performance analysis of the possibility of the chemical interaction between molecule and biological target [12]. Molecular binding affinity, structural stability and propensity for chemical modification of the target are also important factors to gauge the suitability of a target for drug development [13].

B. *Binding Selectivity and Chemical Interactions*

Drug specificity for its target is a function of the nature and strength of chemical interactions formed between the drug molecule and its biological target [13]. These chemical reactions mainly include hydrogen bonds, Van der Waals forces, electrostatic interactions, and hydrophobic interactions, which have different roles in stabilizing the drug–target complex [14]. The nature of these interactions is strongly dependent on the spatial localization of the functional groups in the drug molecule, proper orientation being critical to ensure adequate complementarity with the binding site of their biological target [15]. As shown in Fig. 2, the combined effect of these chemical interactions is that selective binding can be increased and indiscriminate interactions with non-target biomolecules avoided to a larger extent than according to single interaction mechanism, which may lead to improved pharmacological selectivity and therapeutic activity.



Fig. 2. A diagram illustrating the chemical basis for the selective binding of the targeted drug to the biological target.

C. *Structure–Biological Activity Relationship*

The correlation between chemical structures and biological activity is a fundamental concept within pharmaceutical chemistry and forms the cornerstone of rational drug design [16]. Even slight variations to the molecular framework, in terms of functional groups, substituents or the 3D structure can have significant impact on bioactivity, binding and pharmacological selectivity [17]. As depicted in Figure 3, the systematic alteration of chemical structures provides the scientist with an opportunity to explore how certain structural alterations affect the interaction profile with its biological target and leads to an optimization of lead compounds. This could lead to a balanced profile of therapeutic efficacy reduced roadblocks in development with regard to safety and off-target binding, thus highlighting the significance of medicinal chemistry in rational drug design [18].



Fig. 3. Effect of Chemical Structural Modifications on Bioactivity and Target Drug Selectivity.

D. *Improving Physicochemical Properties*

For clinical success of drugs solubility, membrane permeability and chemical stability are very important factors which highly influence the drug discovery and development [19]. Poor physicochemical profiles of drugs are one of the major factors to limit their absorption, dispersion and therapeutic efficacy [20]. As shown in Figure 4, the properties can be drastically affected by rationally tailor made chemical modifications, such as improving solubility and optimizing permeability across biological membranes and better chemical stability. Such advances in the formulations are reflected in both increased bioavailability and treatment efficacy making pharmaceutical chemistry an important element in improving drug action [21].



Fig. 4. Role of Chemical Modifications in Enhancing the Physicochemical Properties of Target Drugs.

IV. The Role of Pharmaceutical Chemistry in Target Drug Development

Pharmaceutical chemistry is relevant from lead substance identification with high molecular propensity to interact with the biological target, through optimization of lead compound structures up to support of preclinical investigations [22]. At the first step, it is a pharmaceutical chemistry that can assist for selection of appropriate molecular structures and corresponding to interactions between compound and

Ayad Jirjees Dhulkefl, Engie Aydin Kamal ALABBAS, and Suad Shallal Shahatha, "The Role of Pharmaceutical Chemistry in the Design and Development of Targeted Medicines: Chemical Principles and Therapeutic Applications," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 9, Issue 2, pp. 54-57, 2026.

biological target as well as counterpart compounds to be designated ones having an appropriate ground for further stage development [23]. In the structural modification stage, the molecule chemical structure is repeatedly altered to provide high selectivity, enhance efficacy and decrease the potential toxicity of lead compounds [24].

These activities are key to lower failure rates in advanced stages of development due to discovery failures, for instance toxicity, poor bioavailability or chemical instability [25]. Pharmaceutical chemistry also helps to optimize the pharmacokinetic profiles of lead compounds through the introduction of rational structural modifications which remove unwanted drug interactions [26], increase in vivo stability, and assist in reaching active therapeutic concentrations [27].

V. Therapeutic Applications of Targeted Drugs

There is a growing trend of high therapeutic successes using targeted drugs in numerous medical areas, most notably in oncology [28]. It permits the directed delivery of anticancer compounds to cellular pathways that control the growth and progression of tumors, with less off-target effect on normal tissue than with conventional chemotherapy [29]. This has led to higher response rates as well as reduced systemic toxicity [30].

They have also been successfully applied in the treatment of chronic inflammatory diseases, cardiovascular and a few neurological disorders [31]. Selective development of drug molecules has led to enhanced treatment benefit and reduced patient burden [32]. This success further emphasizes the value of combining full appreciation of disease mechanisms with systematic application of pharmaceutical chemistry principles to achieve compounds with improved therapeutic performance [33].

VI. Current Challenges in Targeted Drug Development

Although advances are being made in this area, the development of antivirals to target these mechanisms is also a significant challenge [34]. The complexity and poor selectivity of biological targets make it challenging to selectively bind the drugs to them, in addition, drug resistance occurs when taken for a long time [35]. In addition, inter-individual variation of treatment response plays an important role to be considered in final assessment of drug effectiveness and safety [36].

For some biological targets, certain chemical constraints are placed for a desired level of selectivity while avoiding other body targets [37]. Overcoming them requires the creation of more sophisticated chemical strategies, and an increased interaction among pharmaceutical chemistry [38] with life science, and clinical science to guide research toward rational therapeutic approaches [39].

VII. Future Prospects

Further developments in pharmaceutical chemistry will likely enlarge the panel of targeted therapies and generate more selective compounds that may be adapted to various therapeutic needs [40]. In addition, the more direct integration of chemical and biological information with the rapidly innovating field of molecular biology is also likely to lead to reined recognition or biotargets and improved design of both more powerful and safer drugs [41]. Such developments are very hopeful for well targeted precision and specificity which how itself comes as pillars of present day drug treatment [42].

VIII. Conclusion

Intermediate of this review are that the involvement of drug-oriented professional people like medicinal chemist in rational drug design is important and with appropriate application of chemical concept targeting agents should resulted with better sensitivity, selectivity and meanwhile less side effects. Today, prospective studies in this area are very likely to persist and support the development of safer and more effective future targeted therapies.

References

[1] R. Kumar, J. S. Sohal, A. V. Singh, and D. S. Chauhan, Pretomanid for the treatment of drug-resistant pulmonary tuberculosis: a comprehensive review, Archives of Microbiology, vol. 208, no. 1, p. 35, 2026.

[2] L. Guruprasad, S. Saxena, A. Banerjee, and G. Boggarapu, Computational Multi-target Drug Design, in Springer Handbook of Chem-and Bioinformatics, Springer Nature Switzerland, Cham, pp. 627–652, 2026.

[3] N. Carballo-Pedrares, V. M. M. Giménez, and M. J. Alonso, Clinical translation of injectable hydrogels: from bioactive polymers to long-acting drug delivery systems, Drug Delivery and Translational Research, pp. 1–24, 2026.

[4] J. Singh, N. K. Singh, S. Dubey, G. Jaiswal, A. Srivastava, S. P. Telang, and S. K. Srivastava, Novel Molecules and Materials for Drug Discovery, in Experimental and Computational Advances in Materials, Springer Nature Singapore, Singapore, pp. 439–472, 2026.

[5] H. X. Xu, J. Peng, J. L. Yu, X. Hong, Y. Xiao, B. G. Ye, and G. B. Li, Evolution of Molecular Generation Models in Drug Discovery, Journal of Medicinal Chemistry, 2026.

[6] S. Wu, Z. Jin, P. Wang, R. Song, and B. Song, Chemical management of phytopathogenic bacteria: emerging compounds, molecular targets and outlook, Chemical Society Reviews, 2026.

[7] C. M. Drăgoi, A. C. Nicolae, and I. B. Dumitrescu, The Indole Scaffold in Biochemistry and Therapeutics: A Privileged Structure with Diverse Chemical, Biological, and Clinical Significance, Targets, vol. 4, no. 1, p. 4, 2026.

[8] Y. Gu, R. Yang, Y. Zhang, M. Guo, T. Kato, M. Zhan, and H. Wang, Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer, Molecular Biomedicine, vol. 6, no. 1, p. 2, 2025.

[9] Y. Mahendra and H. Dilnashin, Photodrugs: Role of Redox Regulation in Neurodegenerative Diseases, in Phototherapeutic Approaches to Neurodegeneration: Current Trends and Prospects, Springer Nature Singapore, Singapore, pp. 19–45, 2026.

[10] N. B. Jafar, The effect of using gelatin membrane loaded with copper oxide nanoparticles and selenium on some properties of soft cheese, NTU Journal of Agriculture and Veterinary Science, vol. 3, no. 4, 2023.

[11] R. C. Wang and Z. Wang, Precision medicine: disease subtyping and tailored treatment, Cancers, vol. 15, no. 15, p. 3837, 2023.

[12] P. Li, Z. Yan, Y. Zhou, H. Li, W. Gao, and D. Li, Design and Research of a Dual-Target Drug Molecular Generation Model Based on Reinforcement Learning, Inventions, vol. 11, no. 1, p. 12, 2026.

[13] H. Chen, H. Liu, Y. Tian, Y. Liu, F. Tang, J. Huang, and J. Yang, Limited Proteolysis-Coupled Mass Spectrometry (LiP-MS): A Cutting-Edge Tool for De Novo Drug Target Discovery, Journal of Proteome Research, 2026.

[14] J. Huang, M. You, Y. Chen, C. Zhang, and F. Huang, Interactions between lycopene and myofibrillar proteins under different pH

conditions: Implications for structural properties and in vitro digestibility, Food Hydrocolloids, p. 112500, 2026.
[15] Y. Khan, H. Sarfraz, M. Naseem, R. Adnan, S. F. Naqvi, A. Khan, and S. Aminullah, Design, synthesis and biological profiling of bis-thiazole linked Schiff bases as effective enzyme inhibitors for targeting urease and thymidine phosphorylase proteins, Naunyn-Schmiedeberg's Archives of Pharmacology, pp. 1–24, 2026.
[16] Y. Vaishnav, S. Verma, and A. Mishra, The Role of Structure-Activity Relationship (SAR) in Drug Discovery, Indian Journal of Pharmaceutical Chemistry and Analytical Techniques, pp. 67–83, 2025.
[17] E. Omari, E. Davoodi, and H. Dustmohamadi, Medicinal Chemistry: Drug Design Strategies and SAR Optimization, 2025.
[18] S. Wankhede, A. Badule, S. Chaure, A. Damahe, M. Damahe, and O. Porwal, Challenges and strategies in prodrug design: a comprehensive review, Journal of Advanced Scientific Research, vol. 16, no. 6, pp. 1–20, 2025.
[19] M. R. Qelliny, W. W. Mustafa, A. A. Fatease, A. H. Alamri, R. Alany, and H. Abdelkader, Biofunctional excipients: their emerging role in overcoming the inherent poor biopharmaceutical characteristics of drugs, Pharmaceutics, vol. 17, no. 5, p. 598, 2025.
[20] R. Paruparla, M. Lalan, P. Shah, and N. Vasdev, A critical comparative insight on nanocarrier-based intranasal delivery of statins for neuroprotective applications, Pharmaceutical Development and Technology, pp. 1–43, 2026.
[21] A. K. S. Goes, A. Soliman, V. K. Kowthavarpu, P. R. Olivera, and N. V. de Moraes, Enhancing bioavailability of a weakly basic drug through cocrystallization: PBPK modeling of ketoconazole–succinic acid, European Journal of Pharmaceutics and Biopharmaceutics, p. 114986, 2026.
[22] A. Gangwal and A. Lavecchia, Artificial intelligence in natural product drug discovery: current applications and future perspectives, Journal of Medicinal Chemistry, vol. 68, no. 4, pp. 3948–3969, 2025.
[23] S. Thakur, D. Kumar, S. Jaiswal, K. K. Goel, P. Rawat, V. Srivastava, and A. R. Dwivedi, Medicinal chemistry-based perspectives on thiophene and its derivatives: exploring structural insights to discover plausible druggable leads, RSC Medicinal Chemistry, vol. 16, no. 2, pp. 481–510, 2025.
[24] S. A. Alalaf and S. Shihab, Evaluating the environmental and hygienic impacts of veterinary pharmaceuticals: investigating risks and solutions, NTU Journal of Agricultural and Veterinary Sciences, vol. 5, no. 3, 2025.
[25] S. Jacob, R. Rao, B. Gorain, S. H. Boddu, and A. B. Nair, Solid lipid nanoparticles and nanostructured lipid carriers for anticancer phytochemical delivery: advances, challenges, and future prospects, Pharmaceutics, vol. 17, no. 8, p. 1079, 2025.
[26] H. Khude and P. Shende, Structurally modified cyclodextrins in topical nanotechnology: advancing barrier-penetrating drug delivery strategies for psoriasis management, AAPS PharmSciTech, vol. 27, no. 2, p. 84, 2026.
[27] S. Ahmed, A. P. Sakla, K. Jahan, N. Neshat, M. Akhter, S. Aaghaz, and A. Kamal, An overview of recent advancements in targeted cancer therapies and their potential clinical impact, RSC Medicinal Chemistry, 2026.
[28] O. Ashirov, S. Azimova, B. Angelov, and A. Angelova, Engineering liposomes for neurodegenerative diseases: targeted delivery and regenerative potential, ChemNanoMat, vol. 12, no. 1, e202500258, 2026.
[29] A. E. Basyoni, A. Atta, M. M. Salem, and T. M. Mohamed, Harnessing exosomes for targeted drug delivery systems to combat brain cancer, Cancer Cell International, vol. 25, no. 1, p. 150, 2025.
[30] J. Drappatz and M. Mantica, Treatment strategies and innovation for recurrent high-grade glioma, Journal of Neuro-Oncology, vol. 176, no. 1, p. 118, 2026.
[31] O. A. Caliman-Sturdza, J. A. Vaz, A. V. Lupaescu, A. Lobiuc, C. Bran, and R. E. Gheorghita, Antioxidant and anti-inflammatory activities of probiotic strains, International Journal of Molecular Sciences, vol. 27, no. 2, p. 1079, 2026.
[32] A. G. Al Dabbagh, Nanotechnology; the science of present and future (principles and applications), NTU Journal of Pure Sciences, vol. 1, no. 3, pp. 32–39, 2022.
[33] L. Dong, L. Fang, W. Peng, and X. Yang, A comprehensive review: deep learning-powered revolution in antitumor drug research—exploring multimodal data integration and ethical governance framework, Letters in Drug Design & Discovery, 2026.
[34] E. Gonçalves, C. J. Ryan, and D. J. Adams, Synthetic lethality in cancer drug discovery: challenges and opportunities, Nature Reviews Drug Discovery, vol. 25, no. 1, pp. 22–38, 2026.
[35] S. Tauro, B. Dhokchawle, D. Nahar, S. Nadar, E. Thakor, and P. Mohite, Target-based vs phenotypic drug discovery: opportunities and challenges with evidence-based application, Drug Discovery Stories, pp. 25–45, 2025.
[36] D. Otieno, F. W. Ojara, N. Richardson, C. Waitt, P. Zhao, and D. Hartman, Treating pregnant and lactating women: insights from clinical pharmacology, Annual Review of Pharmacology and Toxicology, vol. 66, no. 1, pp. 191–210, 2026.
[37] K. E. Madsen, M. T. Flavin, and J. A. Rogers, Materials advances for distributed environmental sensor networks at scale, Nature Reviews Materials, vol. 11, no. 1, pp. 26–49, 2026.
[38] Q. An, L. Huang, C. Wang, D. Wang, and Y. Tu, New strategies to enhance the efficiency and precision of drug discovery, Frontiers in Pharmacology, vol. 16, p. 1550158, 2025.
[39] K. Elechi, E. Foster-Pagaebi, C. Okolue, A. Adidu, V. C. Ezeamii, A. O. Odenigbo, and C. Onah, A review on evolving role of medical science liaisons in translational medicine, Journal of Pharma Insights and Research, vol. 3, no. 2, pp. 157–165, 2025.
[40] P. C. Collins and J. W. Tom, The role of chemical engineers in the pharmaceutical industry, Annual Review of Chemical and Biomolecular Engineering, vol. 17, 2026.
[41] H. Wang, J. Chen, W. Liu, D. Wang, Y. Song, H. Hong, and J. B. Zimmerman, Using machine learning for green substitution of industrial chemicals: integrating functionality, hazard, and life cycle impact, Chemical Reviews, 2026.
[42] Y. Waly, A. Hussain, A. Al-Majmuei, M. Alatoom, A. J. Alaraibi, A. Alaysereen, and G. R. Deen, Evolution of biosensors and current state-of-the-art applications in diabetes control, Biosensors, vol. 16, no. 1, p. 39, 2026.